Industry Insights

• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
• 
  Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
  April 28, 2025
  PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
• 
  Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
  April 15, 2025
  On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.

• 
  NAD+ Application in Pharmaceutical Industry and Regulatory Status in Multiple Countries and Markets Nurah Ekhlaque
  April 25, 2025
  This article highlights key applications, clinical trial developments, and regulatory classifications of NAD⁺ and its derivatives across major global markets.

• 
  HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
  April 25, 2025
• 
  InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China PharmaSources
  April 27, 2025
• 
  InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
  March 28, 2025
  InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.

• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025
  Popular Products and Companies at PharmaSources.com
• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024

• 
  20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
  December 13, 2024
  Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.